PRINCETON, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Pharmacopeia today announced that the company plans to release its financial results for the third quarter ended September 30, 2005 after the Nasdaq Market closes on Thursday, November 3, 2005. The company will conduct a conference call and an audio webcast at 5:00 p.m. EST on the same day.
Dr. Les Browne, President and Chief Executive Officer, and Mr. Michio Soga, Executive Vice President and Chief Financial Officer, will host the call. Forward-looking and other material information may be discussed on this conference call.
Conference call numbers are as follows: Date: November 3, 2005 Time: 5:00 p.m. EST Domestic Callers: (800) 967-7185 International Callers: (719) 457-2634 Confirmation code: 2472260 Name of Conference: Pharmacopeia Third Quarter 2005 Earnings Release Webcast information: Please visit http://www.pharmacopeia.com
A replay of the conference call can be accessed by dialing toll-free 888-203-1112 in the U.S., or 719-457-0820 outside the U.S. The access code for the replay is 2472260. Replay of the webcast will also be accessible on Pharmacopeia’s website on the “Investors” page at http://www.pharmacopeia.com. The replays will be available for two weeks.
Pharmacopeia creates and delivers novel therapeutics to address significant medical needs. Using proprietary technologies and processes, Pharmacopeia discovers and develops novel drug candidates to advance internally as well as with strategic partners. The company is advancing multiple internal programs - focused primarily on immunobiology and immunological diseases - to validation in clinical trials. Pharmacopeia’s later stage portfolio currently comprises multiple partnered programs that have been advanced into human clinical trials with further programs in late- stage pre-clinical development. Beyond these, the company has several internal programs in advanced pre-clinical optimization and multiple partnered programs in discovery that are expected to drive the company’s clinical portfolio in the future.
Contact: Michio Soga Executive Vice President and Chief Financial Officer Pharmacopeia Drug Discovery, Inc. (609) 452-3643 irreq@pcop.com
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia’s strategic plans, Pharmacopeia’s intentions regarding the establishment and continuation of drug discovery collaborations with leading pharmaceutical and biotechnology organizations, in particular, the continuation and funding level of such continuation of Pharmacopeia’s existing collaborations with Schering-Plough and N.V. Organon, Pharmacopeia’s ability to build its pipeline of novel drug candidates, both through its own internally-funded drug discovery programs and third party collaborations, Pharmacopeia’s ability to raise additional capital, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its Report on Form 10-Q filed on August 5, 2005, its Report on Form 10-K filed on March 23, 2005 and subsequent filings under the Securities and Exchange Act of 1934. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Pharmacopeia
CONTACT: Michio Soga, Executive Vice President and Chief FinancialOfficer, Pharmacopeia Drug Discovery, Inc., +1-609-452-3643, irreq@pcop.com
Web site: http://www.pharmacopeia.com/
